Tremelimumab

Drug Profile

Tremelimumab

Alternative Names: CP-675; CP-675,206; Ticilimumab

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Amgen; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Immunocore; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Pancreatic cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Phase I/II Malignant melanoma; Peritoneal cancer
  • Phase I Colorectal cancer; Diffuse large B cell lymphoma; Renal cell carcinoma
  • No development reported Gastrointestinal cancer; Urogenital cancer

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Endometrial cancer (Combination therapy, Second-line therapy or greater, Recurrent) in USA (IV) (NCT03015129)
  • 23 Dec 2016 City of Hope Medical Center plans a pilot trial in Colorectal cancer (Combination therapy) in USA (NCT03005002)
  • 15 Dec 2016 Breast International Group and UNICANCER plan the phase II ULTIMATE trial for Breast cancer (Combination therapy, Neoadjuvant therapy) in France (IV) (NCT02997995)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top